Auven Therapeutics (formerly Celtic Therapeutics Management L.L.L.P.) was founded in 2007 by Stephen Evans‐Freke and Dr. Peter B. Corr. The Company’s private equity strategy is to acquire promising therapeutic products that have achieved proof of principle in human clinical studies. Auven Therapeutics’ in-house team of senior pharmaceutical development executives then establishes the clinical, manufacturing, regulatory and commercial strategies for the development of its products and oversees its execution. Upon achieving value enhancing milestones including completing Phase III pivotal studies, Auven Therapeutics partners with major pharmaceutical companies for continued development and commercialization.
Based in the U.S. Virgin Islands, Auven Therapeutics has origination, acquisition and development operations in New York City and Lausanne, Switzerland.